Advanced Drug Delivery Market Statistics 2030:
The global advanced drug delivery market size was valued at $44,029.59 million in 2020, and is projected to reach $1,95,132.45 million by 2030, registering a CAGR of 16.0% from 2021 to 2030. The term "advanced drug delivery" refers to the methods, formulations, and processes (routes of administration) used to provide drugs for a variety of uses or therapeutic purposes. Advanced drug delivery is a more controlled means of delivering the drug molecule to the targeted site. Advance drug delivery refers to drug delivery systems that are based on novel drug delivery strategies and make use of cutting-edge technologies. They are designed to deliver drugs in a controlled or modulated way within the tissue or cells, resulting in safe and effective therapy.
The phrase advanced drug delivery (ADD) refers to technologies that control the pace at which drugs are released. The kind of disease, drug, and desired result all have a significant impact on the technology used. The goal of an advanced drug delivery system is to deliver a therapeutic amount of medicine to the specific site in the body as rapidly and effectively as possible in order to achieve and then maintain the target drug concentration.
The ability to deliver a drug more selectively to a specific site; easier, more accurate, less frequent dosing; decreased variability in systemic drug concentrations; absorption that is more consistent with the site and mechanism of action; and reductions in toxic metabolites are all advantages of advanced drug delivery systems over traditional systems. The advanced drug delivery system comprises oral, parenteral, pulmonary, transmucosal, transdermal, carrier based systems like nanoparticles, nanospheres, nanocapsules, nanoemulsions, and nano-sized vesicular carriers, such as liposomes, niosomes, dendrimers, and polymeric or lipid-based carriers and other drug delivery systems
Increasing incidences of chronic diseases in overall population is one of the major factors that drives the market. Chronic diseases are described generally as problems that persist a year or longer and need continuous medical treatment, that limit everyday activities, or both. Furthermore, considerable rise in healthcare expenditure worldwide has boosted the advanced drug delivery market. The major factors that are responsible for the increase in healthcare expenditure are rise in population especially geriatric, rise in chronic diseases and increased medical service utilization. Surge in healthcare spending has further grown due to the consumer awareness for health, rise in initiatives taken by the government, companies and increase in investment by public-private sector companies for the unmet demand in developing and under-developed countries. Thus, all these factors collectively provide opportunity for investments in R & D activities for the development of advanced drug delivery solutions for better drug efficacy and safe therapy for already existing drugs as well as upcoming new molecular entities, which further drives the growth of the market.
Exponential rise in overall population has led to surge in prevalence of chronic diseases as well as emergence of new diseases. This has further increased R&D activities to introduce new drug molecules. Technological advancements have been made to develop advanced drug delivery system by improving pharmacodynamics, drug toxicity, immunogenicity, bio compatibility, pharmacokinetics, and drug efficacy of the compounds by designing various advanced drug delivery routes. Moreover, rise in funding’s & investments by the government, product launches, collaborations for development of advanced drug delivery systems by the key players of the market is expected to significantly boost the growth of the market in the forecast period. However, the considerable rise in number of drug recalls and drug failures is expected to impede the advanced drug delivery market growth.
Impact Of Covid-19 On Advanced Drug Delivery Market (Pre And Post Analysis)
In addition, the COVID-19 outbreak is anticipated to have a positive impact on the growth of the global advanced drug delivery market. A large number of clinics and hospitals throughout the world were reorganized to boost hospital capacity for COVID-19 patients. Due to the rapidly increasing COVID-19 cases, the non-essential processes faced a possible backlog. Furthermore, the lockdown hampered manufacturing and transportation of crucial hospital supplies. Conversely, research studies and activities, including clinical trials for the efficacy and safety, for the treatment of COVID-19 immunization by various researchers, companies, and government boosted the advanced drug delivery market.
Furthermore, untapped, emerging markets are expected to offer potential growth opportunities, due to improved healthcare infrastructure, increase in unmet healthcare needs, and rise in R&D activities. In addition, various technological advancements in drug delivery is an emerging opportunity for key players to invest in the advanced drug delivery market.
Advanced Drug Delivery Market Segmentation
The global advanced drug delivery market is segmented on the basis of product type, end user, and region. On the basis of product type, the market is segregated into drug eluting lens, microneedle patch, hydrogel drug delivery and nano carrier. By end user, it is fragmented into hospitals, specialized clinics and others.
Region wise, the advanced drug delivery market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).
By Product Type
Nano Carrier holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Segment review
Depending on the product type, the nano carrier segment dominated the market in 2020, and is expected to continue this trend during the forecast period, due to increased availability of drug, decreased active drug degradation, lower toxicity and effective targeted therapy.
By end user, the specialized clinics segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period.
North America accounted for a majority of the global advanced drug delivery market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in adoption of advanced technologies, owing to the better adoption of improved drug delivery solutions, presence of key players, and rise in healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in R&D activities, rise in diseases prevalence and increase in investments in the healthcare sector in the region.
The key players operating in the global advanced drug delivery market are Alnylam Pharmaceuticals Inc., Altaris Capital Partners Llc. (Kindeva Drug Delivery), Bausch Health Companies Inc., (Bausch & Lomb), Biogen Limited, Endo International Plc., Johnson & Johnson (Johnson & Johnson Vision), Micropoint Technologies, Novo Nordisk A/S, Ocular Therapeutix Inc. and Takeda Pharmaceutical Company Limited.
By Region
Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 17.9% during the forecast period.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the advanced drug delivery market, and the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing advanced drug delivery market opportunities.
- Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the advanced drug delivery market.
Advanced Drug Delivery Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By END USER |
|
 By Region |
|
 Key Market Players | ALNYLAM PHARMACEUTICALS, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITED, JOHNSON & JOHNSON (JOHNSON & JOHNSON VISION), OCULAR THERAPEUTIX, INC., ENDO INTERNATIONAL PLC., BAUSCH HEALTH COMPANIES INC. (BAUSCH & LOMB), ALTARIS CAPITAL PARTNERS, LLC. (KINDEVA DRUG DELIVERY), MICROPOINT TECHNOLOGIES PTE LTD., BIOGEN LIMITED, NOVO NORDISK |
Analyst Review
This section provides the opinions of the top level CXOs in the global advanced drug delivery market. According to the insights of CXOs, increase in prevalence of chronic diseases, emergence of novel diseases due to genetic mutations, surge in targeted drug delivery and technological advancements are expected to significantly boost the growth of the advanced drug delivery market.
The CXOs further added that rise in drug discovery & development, introduction of novel drugs for the treatment of emerging new diseases, personalization of treatments, advanced formulations and the use of novel drug carriers have been shown to improve the efficiency and efficacy of drug delivery systems, leading to better treatment outcomes. Furthermore, advancement in designing the drug delivery systems for the available drugs by overcoming the limitation related to factors such as adsorption, solubility, toxicity, molecular weight, metabolism, distribution and excretion, notably contributes toward the market growth.
Moreover, the development of improved drug delivery techniques is now preferred before the discovery of novel compounds, due to stringent government regulations. There are several dosage forms into which a drug substance can be incorporated for effective delivery through oral, parenteral, pulmonary, transdermal, transmucosal and other carrier based drug delivery system. Biotechnology and nanotechnology advancements have considerably accelerated the development of innovative drug delivery techniques.
The market gains interest of healthcare companies, owing to surge in R&D and increase in focus in adoption of advanced drug delivery for safe and effective therapy.
North America is expected to witness highest growth, in terms of revenue, owing to rapidly growing geriatric population, robust R&D infrastructure for life science researches, rapid adoption of adoption of advanced technologies, improved drug delivery solutions, presence of key players, and advancements in healthcare investments. Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register the fastest CAGR during the forecast period, due to the continuous government support for pharmaceutical and biotechnology R&D, increase in public–private investments, and rise in number of research activities in the healthcare sector for improved and efficient drug delivery.
The total market value of advanced drug delivery market is $44,029.59 million in 2020.
The forecast period for advanced drug delivery market is 2021 to 2030
The market value of advanced drug delivery market in 2021 is $51,183.67million.
The base year is 2020 in advanced drug delivery market
Top companies such as Alnylam Pharmaceuticals Inc., Altaris Capital Partners Llc. (Kindeva Drug Delivery), Bausch Health Companies Inc., (Bausch & Lomb), Biogen Limited, Endo International Plc., Johnson & Johnson (Johnson & Johnson Vision), Micropoint Technologies, Novo Nordisk A/S, Ocular Therapeutix Inc. and Takeda Pharmaceutical Company Limited held a high market position in 2020.
Nano carrier segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to their increased drug availability, reduced active drug degradation and further technological advancements is expected to drive the segment
Increase in prevalence of chronic diseases, advanced infrastructure for research & development and investments in healthcare is anticipated to drive the market in the forecast period.
North America is projected to account for a major share of the global advanced drug delivery market during the forecast period. Asia-Pacific is projected to offer lucrative oppurtunities due to increase in prevalence of chronic diseases, rise in investments for drug discovery in the R & D sector due to presence of key players across the region.
Loading Table Of Content...
